| 32.695 0.875 (2.75%) | 11-14 12:44 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.29 | 1-year : | 45.89 |
| Resists | First : | 33.63 | Second : | 39.29 |
| Pivot price | 31.5 |
|||
| Supports | First : | 29.04 |
Second : | 26.2 |
| MAs | MA(5) : | 31.94 |
MA(20) : | 30.92 |
| MA(100) : | 25.86 |
MA(250) : | 23.22 |
|
| MACD | MACD : | 1 |
Signal : | 1 |
| %K %D | K(14,3) : | 74 |
D(3) : | 68.4 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 33.63 | Low : | 13.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IDYA ] has closed below upper band by 12.5%. Bollinger Bands are 13.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.49 - 32.67 | 32.67 - 32.82 |
| Low: | 31.14 - 31.36 | 31.36 - 31.54 |
| Close: | 31.49 - 31.82 | 31.82 - 32.11 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Tue, 11 Nov 2025
IDEAYA Biosciences (IDYA): Assessing Valuation After Swing to Profit and Strong Quarterly Turnaround - simplywall.st
Sun, 09 Nov 2025
IDEAYA Biosciences (IDYA) Is Down 5.1% After Return to Profitability and Strong Q3 Earnings - Has The Bull Case Changed? - simplywall.st
Tue, 04 Nov 2025
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
Tue, 04 Nov 2025
IDEAYA Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView
Fri, 31 Oct 2025
IDEAYA Biosciences (NASDAQ: IDYA) awards 73,500 inducement options with 4-year vesting - Stock Titan
Mon, 27 Oct 2025
IDEAYA Biosciences (NASDAQ: IDYA) schedules Nov. 6 and Nov. 18 investor events; webcasts - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 8.182e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 9,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.8176e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 488.9 % |
| Return on Equity (ttm) | -23.9 % |
| Qtrly Rev. Growth | 7e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -250.65 |
| EBITDA (p.s.) | -2.39607e+009 |
| Qtrly Earnings Growth | -3.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -294 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 0.42 |
| Dividend | 0 |
| Forward Dividend | 8.48e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|